Home Ingredients VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)
Cardiovascular

VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)

Evidence Level
Limited
3 Clinical Trials
4 Documented Benefits
2/5 Evidence Score

VasoDrive-AP® (distributed by Maypro; the same casein tripeptide ingredient sold as AmealPeptide, made by Asahi/Calpis) supplies the casein-derived lactotripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP). These milk peptides inhibit angiotensin-converting enzyme (ACE) in the test tube, but controlled human studies show they are poorly absorbed and do not meaningfully inhibit ACE in the body, so any blood-pressure effect is small. This is distinct from the site's generic casein-protein entry: casein protein is a bulk dietary protein, whereas VasoDrive-AP® is a concentrated source of the specific BP-active tripeptides. Honest framing: meta-analyses show a modest blood-pressure reduction with notable heterogeneity, and effects tend to be smaller and less consistent in Western/European populations than in Japanese trials.

Studied Dose Trials used roughly 3 to 11 mg/day of combined IPP+VPP (for example 4.5 mg IPP and 6.6 mg VPP daily in the human ACE study). Effects over placebo were small at these doses.
Active Compound Lactotripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP) from casein hydrolysate. VasoDrive-AP® (Maypro); same ingredient as AmealPeptide (Asahi/Calpis).

Benefits

Healthy Blood Pressure Support

In European randomized trials the combined IPP/VPP effect over placebo was about 1.3 mmHg systolic (Cicero 2013); larger effects come mainly from company-run Japanese trials. EFSA reviewed the exact IPP/VPP blood-pressure claim in 2011 and 2012 and concluded a cause-and-effect relationship was not established. Honest context: pooled trial effects are modest in size and vary between populations, so VasoDrive-AP® is best viewed as a supportive food-derived peptide for blood pressure already in the normal-to-high-normal range, not a treatment for diagnosed high blood pressure (hypertension).

Supported by Trial 1, Trial 2

Targeted Bioactive Peptides

Unlike bulk casein protein, VasoDrive-AP® concentrates the specific tripeptides responsible for the blood-pressure signal. This makes it a defined, standardized way to obtain IPP/VPP rather than relying on dietary dairy intake.

Supported by Trial 1, Trial 2

Vascular Function Support

By gently modulating the renin-angiotensin system, lactotripeptides may support healthy vascular tone and endothelial function. The effect is mild and best viewed as part of an overall heart-healthy lifestyle.

Supported by Trial 3, Trial 1

Well-Tolerated Milk-Peptide Source

Lactotripeptides are food-derived peptides with a long history of use in functional foods and a favorable tolerability profile, making them an option for people seeking gentle, food-based cardiovascular support.

Supported by Trial 1, Trial 3

Mechanism of action

1

ACE Inhibition

IPP and VPP inhibit angiotensin-converting enzyme (ACE) in laboratory assays. In people, however, the tripeptides are poorly absorbed and a controlled human study found they did not lower plasma or endothelial ACE activity at food doses, whereas the drug captopril cut plasma ACE by about 82 percent. This mechanism therefore operates weakly, if at all, in the body and does not match a pharmaceutical ACE inhibitor.

2

Renin-Angiotensin Modulation

By dampening angiotensin II formation, the tripeptides can promote vasodilation and reduce vascular resistance, which underlies their modest blood-pressure effect observed in trials.

3

Proline-Rich Peptide Stability

The proline residues in IPP/VPP confer resistance to digestive proteases, allowing a fraction of these tripeptides to survive digestion and reach circulation intact — important for their bioactivity as food-derived peptides.

Clinical trials

1
Lactotripeptides and Blood Pressure (Pooled)
PubMed

Meta-analysis of randomized controlled trials of IPP/VPP lactotripeptides as functional foods on blood pressure.

Pooled across lactotripeptide randomized trials.

Lactotripeptides were associated with modest reductions (on the order of a few mmHg) in systolic and diastolic blood pressure, with significant heterogeneity between studies. Supports a measured claim of healthy blood-pressure support rather than a large antihypertensive effect.

2
Lactotripeptides in European Subjects
PubMed

Meta-analysis of randomized controlled trials examining whether IPP/VPP reduce systolic blood pressure specifically in European populations.

European adults across randomized trials.

The blood-pressure effect was more convincing in subjects of Asian origin and less consistent in European populations. This supports the honest, population-dependent framing for VasoDrive-AP®.

3
Milk Proteins and Peptides Review
PubMed

Review of human intervention studies on the impact of milk proteins and peptides, including casein-derived lactotripeptides, on blood pressure and vascular function.

Review of human intervention studies.

The review found accumulating but variable-quality evidence for blood-pressure and vascular benefits of milk proteins/peptides, again underscoring that effects are modest and not uniformly replicated.

Side effects and drug interactions

Common Potential side effects

Generally well tolerated as food-derived peptides.
Mild digestive upset possible.
Not suitable for people with milk-protein allergy.
Possible additive effect with blood-pressure-lowering therapy; monitor.
Limited specific safety data in pregnancy and lactation.

Important Drug interactions

ACE inhibitors (e.g., lisinopril, ramipril) — theoretical additive ACE inhibition; monitor blood pressure.
Other antihypertensives — possible additive blood-pressure lowering; monitor.
Potassium-sparing diuretics — use caution given shared renin-angiotensin effects; monitor potassium.
Generally minimal interactions outside cardiovascular medications.

More Cardiovascular Ingredients

Cardiovascular
Omega-3 Fatty Acids
Omega-3 fatty acids are polyunsaturated fats. EPA and DHA come from fish, krill and algae…
Cardiovascular
CoEnzyme Q10
Coenzyme Q10 (CoQ10) is a fat-soluble compound the body makes for itself. It carries elect…
Cardiovascular
Beetroot
Beetroot is a vegetable rich in dietary nitrate, which the body converts into nitric oxide…
Cardiovascular
Potassium
Potassium is the main mineral inside the body's cells and an essential nutrient for the el…

Explore Other Ingredients

Metabolic Health
Magnesium
Magnesium is an essential mineral and a cofactor in more than 300 enzyme systems, includin…
Athletic Performance
L-Carnitine
L-carnitine is a nutrient the body uses to carry long-chain fats into mitochondria, the ce…

Related articles from our blog

📝 Article
Peptides: Which Are Legal Supplements, and Which Are Not
Peptides are having a moment. They are in face serums and protein powders, in viral videos about "peptide therapy" and w…
June 12, 2026

Frequently asked questions about VasoDrive-AP® (Casein-Derived Lactotripeptides IPP/VPP)

What is VasoDrive-AP?

VasoDrive-AP® (distributed by Maypro; the same casein tripeptide ingredient sold as AmealPeptide, made by Asahi/Calpis) supplies the casein-derived lactotripeptides isoleucyl-prolyl-proline (IPP) and valyl-prolyl-proline (VPP).

What is VasoDrive-AP used for?

VasoDrive-AP is researched primarily for Cardiovascular. In European randomized trials the combined IPP/VPP effect over placebo was about 1.3 mmHg systolic (Cicero 2013); larger effects come mainly from company-run Japanese trials.

What is the recommended dosage of VasoDrive-AP?

The clinically studied dose is Trials used roughly 3 to 11 mg/day of combined IPP+VPP (for example 4.5 mg IPP and 6.6 mg VPP daily in the human ACE study). Effects over placebo were small at these doses. Always follow the product label and check with a healthcare provider for personal advice.

Is VasoDrive-AP safe, and does it have side effects?

For most healthy adults, VasoDrive-AP is well tolerated at studied doses. Reported effects can include: Generally well tolerated as food-derived peptides. Mild digestive upset possible. It may also interact with some medications. VasoDrive-AP is not right for everyone, so check with a healthcare provider first if you are pregnant or breastfeeding, have a medical condition, or take prescription medication.

Does VasoDrive-AP interact with any medications?

Possible interactions include: ACE inhibitors (e.g., lisinopril, ramipril) — theoretical additive ACE inhibition; monitor blood pressure. Other antihypertensives — possible additive blood-pressure lowering; monitor. If you take prescription medication, check with a pharmacist or doctor before using it.

How strong is the scientific evidence for VasoDrive-AP?

NutraSmarts rates the evidence for VasoDrive-AP as Limited (2 out of 5). It is backed by 3 clinical trials and 4 cited references summarized on this page. A higher rating reflects more, larger, and better-designed human studies.

References(4 citations)

Evidence ratings on NutraSmarts are based on the totality of human clinical research, with emphasis on randomized controlled trials, meta-analyses, and systematic reviews. The references below directly support claims made throughout this page.

  1. Cicero AF, Gerocarni B, Laghi L, Borghi C. Blood pressure lowering effect of lactotripeptides assumed as functional foods: a meta-analysis of current available clinical trials. J Hum Hypertens. 2011;25(7):425-36. doi: 10.1038/jhh.2010.85.PubMedUsed to support: Backs the modest blood-pressure benefit: pooled lactotripeptide trials showed a statistically significant but modest reduction in blood pressure.
  2. Cicero AF, Aubin F, Azais-Braesco V, Borghi C. Do the lactotripeptides isoleucine-proline-proline and valine-proline-proline reduce systolic blood pressure in European subjects? A meta-analysis of randomized controlled trials. Am J Hypertens. 2013;26(3):442-9. doi: 10.1093/ajh/hps044.PubMedUsed to support: rewriteSupports
  3. Fekete AA, Givens DI, Lovegrove JA. The impact of milk proteins and peptides on blood pressure and vascular function: a review of evidence from human intervention studies. Nutr Res Rev. 2013;26(2):177-90. doi: 10.1017/S0954422413000139.PubMedUsed to support: Supports the vascular/BP context for casein-derived peptides while noting variable study quality and modest, inconsistent effects.
  4. Wuerzner G, Peyrard S, Blanchard A, Lalanne F, Azizi M. The lactotripeptides isoleucine-proline-proline and valine-proline-proline do not inhibit the N-terminal or C-terminal angiotensin converting enzyme active sites in humans. J Hypertens. 2009;27(7):1404-9. doi: 10.1097/HJH.0b013e32832b4759.PubMedUsed to support: addReference